MRC1 and neoplasm: Except for certain subgroups indicated below, no statistically significant difference in OS or PFS was found between T and R across all examined subgroups, including age, ECOG performance status, RAS status, metastatic sites, sex, prior biologic therapy, MMR status, primary tumour location, use of rechallenge therapy, and adjuvant therapy.